First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial Plasma samples were ...
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback